

## **Amoéba publishes a first scientific article concerning its biocontrol application to fight grapevine downy mildew**

**Chassieu (France), August 11 2020 - AMOÉBA (FR0011051598 - AMEBA)**, producer of a biological biocide capable of eliminating the risk in water and human wounds, and of a biocontrol product for plant protection, still in the testing phase, announces the publication of a first scientific article on its biocontrol application (<https://www.mdpi.com/2223-7747/9/8/1013/pdf>) in the special issue « Natural Products for Plant Pest and Disease Control » of *Plants*, journal of the MDPI Group, peer-reviewed.

This paper presents, for the first time to the international scientific community, a major innovation in the field of biocontrol involving a natural product based on an amoeba, *Willaertia magna* C2c Maky. Scientific data demonstrating the dual mode of action of the lysate to control grapevine downy mildew are presented :

- the indirect effect via the stimulation of the plant's natural defences
- and the direct anti-germinative effect against the pathogen, *Plasmopara viticola*, responsible for grapevine downy mildew.

The data, collected in trials carried out by independent service providers, that have demonstrated efficiency in greenhouses and in the field (2019 season) are also published. **They show that lysate of the amoeba *Willaertia magna* C2c Maky, a product of natural origin, can reduce the disease on bunches in the field by 77% without any harmful effects on humans or the environment.** Indeed, a summary of toxicity and ecotoxicity data, generated under Good Laboratory Practices by accredited independent laboratories are also available on the website of the journal (<http://www.mdpi.com/2223-7747/9/8/1013/s1>).

*« This first article, dealing with the efficacy of our biocontrol solution against grapevine downy mildew, is part of an ongoing effort to increase scientific knowledge on the amoeba *Willaertia magna* C2c Maky. It confirms its strong potential, this time as a plant protection agent. We are continuing R&D operations and tests on other crops, the results of which will also be the subject of new publications, » says Dr Sandrine DEMANECHÉ, scientific manager of Amoéba.*

As a reminder, the marketing of biocontrol products containing this active substance is envisaged by Amoéba in 2024 in Europe (dossier submitted, cf. Press Release of 29 May 2020) and in the first half of 2022 in the United States (submission envisaged in July 2020, cf. Press Release of 29 April 2020, postponed to September 2020). The prioritization of Amoéba's Regulatory Affairs Department resources on biocontrol application leads to a delay in the filing of a new application for biocidal application in the United States, which was envisaged in mid 2020 (see Universal Registration Document of April 30, 2020) and will be submitted at the end of 2020, with first marketing in the United States estimated in the first half of 2022.



#### **About AMOEBA:**

Amoéba's ambition is to become a major player in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn (1) on a global chemical biocide market for water treatment, evaluated at €21Bn (2) and on the biocontrol market for plant protection estimated globally at €1.6Bn (4). In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million (3) in the USA. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations. The Company is currently in a trial phase for biocidal and plant protection applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on the compartment C of Euronext Paris. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on [www.amoeba-biocide.com](http://www.amoeba-biocide.com).

(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013

(2): Sources combined by Amoéba from water treaters, Freedomia, Eurostat et MarketsandMarkets

(3): BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017

(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

#### **Contacts:**

##### **Amoéba**

Valérie FILIATRE

General Manager

+33 4 26 69 16 00

[valerie.filiatre@amoeba-biocide.com](mailto:valerie.filiatre@amoeba-biocide.com)

##### **Investors and Media Relations**

Grégory BOSSON / Mathieu CALLEUX

Agence Calyptus

+33(0)1 53 65 37 90

[amoeba@calyptus.net](mailto:amoeba@calyptus.net)

#### **Disclaimer**

This press release contains certain forward-looking statements concerning AMOEBA which are based on its own assumptions and hypothesis and on information that are available to us. However, AMOEBA gives no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the Universal Registration Document of AMOEBA filed with the French Financial Markets Authority (Autorité des Marchés Financiers) on April 30, 2020 under number D20-0416 (a copy of which is available on [www.amoeba-biocide.com](http://www.amoeba-biocide.com)). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOEBA or not currently considered material by AMOEBA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of AMOEBA to be materially different from such forward-looking statements.